Cargando…
Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V(2)-Receptor Antagonist Tolvaptan
Hyponatremia is common in patients with cirrhosis and portal hypertension, and is characterized by excessive renal retention of water relative to sodium due to reduced solute-free water clearance. The primary cause is increased release of arginine vasopressin. Hyponatremia is associated with increas...
Autores principales: | Gaglio, Paul, Marfo, Kwaku, Chiodo, Joseph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472061/ https://www.ncbi.nlm.nih.gov/pubmed/22732834 http://dx.doi.org/10.1007/s10620-012-2276-3 |
Ejemplares similares
-
Hyponatremia: A role for vasopressin receptor antagonists?
por: Ramesh, Gourishankar
Publicado: (2018) -
Vasopressin Receptor Antagonists in Hyponatremia: Uses and Misuses
por: Rondon-Berrios, Helbert, et al.
Publicado: (2017) -
Hyponatremia Associated with Congestive Heart Failure: Involvement of Vasopressin and Efficacy of Vasopressin Receptor Antagonists
por: Ishikawa, San-e, et al.
Publicado: (2023) -
Management Strategies and Outcomes for Hyponatremia in Cirrhosis in the Hyponatremia Registry
por: Sigal, Samuel H., et al.
Publicado: (2018) -
Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia
por: Hayashi, Manabu, et al.
Publicado: (2018)